Overexpression of apolipoprotein B attenuates pathologic cardiac remodeling and hypertrophy in response to catecholamines and after myocardial infarction in mice

References

• Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569–82.
   PubMed Web of Science ®Google Scholar
• Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215–62.
   PubMed Web of Science ®Google Scholar
• Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Ther 2006;11:31–45.
   PubMed Web of Science ®Google Scholar
• Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784–9.
   PubMed Web of Science ®Google Scholar
• Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003;111:419–26.
   PubMed Web of Science ®Google Scholar
• Chiu H-C, Kovacs A, Ford DA, Hsu F-F, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001;107:813–22.
   PubMed Web of Science ®Google Scholar
• Chiu H-C, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005;96:225–33. .
   PubMed Web of Science ®Google Scholar
• Son N-H, Park T-S, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang L-S, Goldberg IJ. Cardiomyocyte expression of PPAR{gamma} leads to cardiac dysfunction in mice. 2007;117(10)2791–801.
   Google Scholar
• Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Int Med 2005;258:395–410.
   PubMed Web of Science ®Google Scholar
• Nielsen LB, Veniant M, Boren J, Raabe M, Wong JS, Tam C, Flynn L, Vanni-Reyes T, Gunn MD, Goldberg. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation 1998;98:13–6.
   PubMed Web of Science ®Google Scholar
• Boren J, Veniant MM, Young SG. Apo B100-containing lipoproteins are secreted by the heart. J Clin Invest 1998;101:1197–202.
   PubMed Web of Science ®Google Scholar
• Madsen EM, Lindegaard MLS, Andersen CB, Damm P, Nielsen LB. Human placenta secretes apolipoprotein B-100-containing lipoproteins. J Biol Chem 2004;279:55271–6.
   PubMed Web of Science ®Google Scholar
• Krzystanek M, Pedersen TX, Bartels ED, Kjaehr J, Straarup EM, Nielsen LB. Expression of apolipoprotein B in the kidney attenuates renal lipid accumulation. J Biol Chem 2010;285:10583–90.
   PubMed Web of Science ®Google Scholar
• Bjorkegren J, Veniant M, Kim SK, Withycombe SK, Wood PA, Hellerstein MK, Neese RA, Young SG. Lipoprotein secretion and triglyceride stores in the heart. J Biol Chem 2001;276:38511–7.
   PubMed Web of Science ®Google Scholar
• Kim E, Young SG. Genetically modified mice for the study of apolipoprotein B. J Lipid Res 1998;39:703–23.
   PubMed Web of Science ®Google Scholar
• Ramunddal T, Lindbom M, Scharin-Tang M, Stillemark-Billton P, Boren J, Omerovic E. Overexpression of apolipoprotein-B improves cardiac function and increases survival in mice with myocardial infarction. Biochem Biophys Res Commun 2009;385:336–40.
   PubMed Web of Science ®Google Scholar
• Zhang G-X, Ohmori K, Nagai Y, Fujisawa Y, Nishiyama A, Abe Y, Kimura S. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 2007;42:804–11.
   Google Scholar
• Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki I, Sasaki T, Irie-Sasaki J, Gidrewicz D, Rybin VO, Wada T, Steinberg SF, Backx PH, Penninger JM. Phosphoinositide 3-kinase {gamma}-deficient mice are protected from isoproterenol-induced heart failure. Circulation 2003;108:2147–52.
   PubMed Web of Science ®Google Scholar
• Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, Youker KA, Taegtmeyer H. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002;51:2587–95.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Dalton N, Mao L, Rockman HA, Peterson KL, Gottshall KR, Hunter JJ, Chien KR, Ross J. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 1996;94:1109–17.
   PubMed Web of Science ®Google Scholar
• Pollick C, Hale SL, Kloner RA. Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 1995;8:602–10.
   PubMedGoogle Scholar
• Alexander G, Willi R, Toktam H, Oliver D, Djoufack PC, Klaus BF, Jan S, Thorsten L, Berndt L, Klaus T. Echocardiographic assessment of left ventricular mass in neonatal and adult mice: accuracy of different echocardiographic methods. Echocardiography 2006;23:900–7.
   Google Scholar
• Aurigemma GP, Gaasch WH, Villegas B, Meyer TE. Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. Curr Probl Cardiol 1995;20:361–440.
   PubMedGoogle Scholar
• Salto-Tellez M, Yung Lim S, El-Oakley RM, Tang TP, ZA AL, Lim SK. Myocardial infarction in the C57BL/6J mouse: a quantifiable and highly reproducible experimental model. Cardiovasc Pathol 2004;13:91–7.
   Google Scholar
• Kumar D, Hacker TA, Buck J, Whitesell LF, Kaji EH, Douglas PS, Kamp TJ. Distinct mouse coronary anatomy and myocardial infarction consequent to ligation. Coron Artery Dis 2005;16:41–4.
   Web of Science ®Google Scholar
• Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123–4.
   PubMed Web of Science ®Google Scholar
• Winkens B, van Breukelen GJ, Schouten HJ, Berger MP. Randomized clinical trials with a pre- and a post-treatment measurement: repeated measures versus ANCOVA models. Contemp Clin Trials 2007;28:713–9.
   PubMed Web of Science ®Google Scholar
• Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. Faseb J 2004;18:1692–700.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, Goldberg IJ. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 2004; 279:4204–11.
   PubMed Web of Science ®Google Scholar
• Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E, Perriard J-C, Larsen T, Pedrazzini T, Krek W. Activation of a HIF1[alpha]-PPAR[gamma] axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metabolism 2009;9:512–24.
   PubMed Web of Science ®Google Scholar
• Shewan LG, Coats AJS. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1–2.
   Web of Science ®Google Scholar